Prevention of non-communicable diseases: What can be done?

Archives of Iranian Medicine

Volumn 16, Issue 3, 2013, Pages 136-137

  Merat, Shahin ^a   Malekzadeh, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASES; EDITORIAL; HEALTH CARE DELIVERY; HUMAN; LIFESTYLE MODIFICATION; MEDICAL CARE; NONCOMMUNICABLE DISEASE; OBESITY; PREVENTIVE MEDICINE; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE;

EID: 84874616900     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Sarraf-Zadegan N, Sadri G, Malek Afzali H, Baghaei M, Moham-madi Fard N, Shahrokhi S, et al. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol. 2003; 58(4): 309-320.
2. World Development Indicators. Available from: URL: http://data. worldbank.org/country/iran-islamic-republic (Accessed Date: 10/2/2013).
3. NCD mortality and morbidity. World Health Organization, 2012. Available from: URL: http://www.who.int/gho/ncd/mortality_mor-bidity/en/index.html (Accessed Date: 10/2/2013).
4. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sad-jadi AR, et al. Cohort Profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010; 39(1): 52-59.
5. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of Cardiovascular Diseases in an Iranian Population: The Isfahan Cohort Study. Arch Iran Med. 2013. 16(3): 138-144.
6. UN High-Level Meeting puts NCDs on the map, falls short of setting goals or targets. Available from: URL: http://www.ncdalliance.org/node/3517 (Accessed Date: 10/2/2013).
7. Sepanlou SG, Kamangar F, Poustchi H, Malekzadeh R. Reducing the burden of chronic diseases: a neglected agenda in Iranian health care system, requiring a plan for action. Arch Iran Med. 2010; 13(4): 340-350.
8. Sarrafzadegan N, Kelishadi R, Sadri G, Malekafzali H, Pourmoghad-das M, Heidari K, et al. Outcomes of a comprehensive healthy lifestyle program on cardiometabolic risk factors in a developing country: the Isfahan Healthy Heart Program. Arch Iran Med. 2013; 16(1): 4-11.
9. Sepanlou SG, Poustchi H, Kamangar F, Malekzadeh R. Effectiveness and feasibility of lifestyle and low-cost pharmacologic interventions in the prevention of chronic diseases: a review. Arch Iran Med. 2011; 14(1): 46-53.
10. Puska P. Community-based cardiovascular prevention programs: theory and practice. Arch Iran Med. 2013;16(1): 2-3.
11. Fahimi S, Pharoah P. Reducing salt intake in Iran: priorities and challenges. Arch Iran Med. 2012; 15(2): 110-112.
12. WHO Global Health Observatory. Available from: URL: http://apps. who.int/ghodata/?theme=country (Accessed Date: 10/2/2013).
13. Farzadfar F, Murray CJ, Gakidou E, Bossert T, Namdaritabar H, Alikhani S, et al. Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behvarz workers) in Iran: a nationally representative observational study. Lancet. 2012; 379(9810): 47-54.
14. POLYIRAN in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranian. Available from: URL: http://clinicaltrials.gov/ct2/show/NCT01271985 (Accessed Date: 10/2/2013).
15. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326(7404): 1419.
16. Sepanlou SG, Farzadfar F, Jafari E, Danaei G. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated metaanalyses and mortality estimation. Arch Iran Med. 2012; 15(9): 531-537.
17. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nat-eghi A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract. 2010; 64(9): 1220-1227.